Research programme: siRNA therapeutics - Silence Therapeutics

Drug Profile

Research programme: siRNA therapeutics - Silence Therapeutics

Alternative Names: Atu014; Atu093; Atu111; Atu134; Atu150; Atu195; AtuRNAi; Soluble Fms-like Tyrosine Kinase-1-specific SiRNA

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Atugen AG
  • Developer Charite of Berlin; McGill University; Sanofi; Silence Therapeutics; Silence Therapeutics plc
  • Class Antihyperglycaemics; Antihypertensives; Antineoplastics; Small interfering RNA
  • Mechanism of Action Endothelin A receptor antagonists; Protein kinase N3 inhibitors; RNA interference; Vascular endothelial growth factor receptor-1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Acute lung injury; Solid tumours

Highest Development Phases

  • Preclinical Preeclampsia; Pulmonary arterial hypertension
  • No development reported Acute lung injury
  • Discontinued Diabetes mellitus; Solid tumours; Wounds

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Acute-lung-injury in Germany (Parenteral)
  • 14 Sep 2017 Preclinical trials in Preeclampsia in England (IV)
  • 14 Sep 2017 Pharmacodynamics data from a preclinical study in Preclampsia presented at the Council on Hypertension Scientific Session 2017 (AHA-ASH-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top